Dynamic susceptibility contrast MRI measures of relative cerebral blood volume continue to show promise as an early response marker in the setting of bevacizumab treatment.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. Multiparametric MRI for early identification of therapeutic response in recurrent glioblastoma treated with immune checkpoint inhibitors.Neuro-oncology · 2020
   Article
2. Imaging of intratumoral heterogeneity in high-grade glioma.Cancer letters · 2020
   Review
3. Conventional and advanced magnetic resonance imaging in patients with high-grade glioma.The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of... · 2018
   Review

Corrections and comments

• Commented on by
  Evidence for rCBV as an early response marker following bevacizumab treatment.2015
• Comment on
  Predictive imaging marker of bevacizumab efficacy: perfusion MRI.2015

Authors and funding

4 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as